-
EP3740761
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3740761
| EP3740761 - COMPANION DIAGNOSTIC FOR NSAIDS AND DONEPEZIL FOR TREATING SPECIFIC SUBPOPULATIONS OF PATIENTS SUFFERING FROM ALZHEIMER'S DISEASE [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 15.12.2023 Database last updated on 15.06.2024 | |
| Former | Request for examination was made Status updated on 23.10.2020 | ||
| Former | The international publication has been made Status updated on 27.07.2019 | Most recent event Tooltip | 19.04.2024 | Change: Despatch of examination report + time limit | 19.04.2024 | New entry: Reply to examination report | Applicant(s) | For all designated states University of North Texas Health Science Center at Fort Worth 3500 Camp Bowie Boulevard Fort Worth, TX 76107 / US | [2020/48] | Inventor(s) | 01 /
O'BRYANT, Sid, E. 1517 Greenleaf Drive Aledo, TX 76008 / US | [2020/48] | Representative(s) | Barker Brettell LLP 100 Hagley Road Edgbaston Birmingham B16 8QQ / GB | [2020/48] | Application number, filing date | 19741031.9 | 14.01.2019 | [2020/48] | WO2019US13498 | Priority number, date | US201862618857P | 18.01.2018 Original published format: US 201862618857 P | [2020/48] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2019143562 | Date: | 25.07.2019 | Language: | EN | [2019/30] | Type: | A1 Application with search report | No.: | EP3740761 | Date: | 25.11.2020 | Language: | EN | The application published by WIPO in one of the EPO official languages on 25.07.2019 takes the place of the publication of the European patent application. | [2020/48] | Search report(s) | International search report - published on: | KR | 25.07.2019 | (Supplementary) European search report - dispatched on: | EP | 22.09.2021 | Classification | IPC: | G01N33/68 | [2020/48] | CPC: |
G01N33/9486 (EP);
G01N33/5008 (US);
G01N33/6869 (US);
G01N33/6896 (EP);
G01N33/944 (EP);
G01N2800/2821 (EP);
G01N2800/52 (EP)
(-)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2020/48] | Title | German: | BEGLEITDIAGNOSTIK FÜR NSAIDS UND DONEPEZIL ZUR BEHANDLUNG SPEZIFISCHER SUBPOPULATIONEN VON PATIENTEN, DIE AN MORBUS ALZHEIMER LEIDEN | [2020/48] | English: | COMPANION DIAGNOSTIC FOR NSAIDS AND DONEPEZIL FOR TREATING SPECIFIC SUBPOPULATIONS OF PATIENTS SUFFERING FROM ALZHEIMER'S DISEASE | [2020/48] | French: | DIAGNOSTIC COMPAGNON POUR AINS ET DONÉPÉZIL POUR LE TRAITEMENT DE SOUS-POPULATIONS SPÉCIFIQUES DE PATIENTS SOUFFRANT DE LA MALADIE D'ALZHEIMER | [2020/48] | Entry into regional phase | 31.07.2020 | National basic fee paid | 31.07.2020 | Search fee paid | 31.07.2020 | Designation fee(s) paid | 31.07.2020 | Examination fee paid | Examination procedure | 31.07.2020 | Examination requested [2020/48] | 07.04.2022 | Amendment by applicant (claims and/or description) | 18.12.2023 | Despatch of a communication from the examining division (Time limit: M06) | 18.04.2024 | Reply to a communication from the examining division | Fees paid | Renewal fee | 13.01.2021 | Renewal fee patent year 03 | 31.12.2021 | Renewal fee patent year 04 | 12.01.2023 | Renewal fee patent year 05 | 11.01.2024 | Renewal fee patent year 06 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [A]WO9840061 (UNIV LOMA LINDA MED [US]); | [A]US2014018446 (ROYALL DONALD R [US], et al); | [Y]WO2014066318 (GEN HOSPITAL CORP [US], et al); | [XYI]US2016291036 (O'BRYANT SID E [US]) | International search | [A]US2010280562 (PI BO [US], et al) [A] 27-31, 53, 55-58* See the whole document. *; | [A]US2014147863 (O'BRYANT SIDNEY E [US], et al) [A] 27-31, 53, 55-58 * See the whole document. *; | [X]US2016291036 (O'BRYANT SID E [US]) [X] 27-31, 53, 55-58 * See paragraphs [0010], [0109]; claims 110-117, 123-124, 129-134. *; | [X] - O'BRYANT, SID et al., "A proinflammatory endophenotype predicts treatment response in a multicenter trial of NSAIDs in AD", Alzheimer's & dementia: the journal of the Alzheimer's Association, (20140000), vol. 10, no. 4, pages P273 - P274, XP055629766 [X] 27-28, 31, 53, 55, 58 * See P273-P274. * DOI: http://dx.doi.org/10.1016/j.jalz.2014.04.447 | [A] - O'BRYANT, SID E. et al., A serum protein-based algorithm for the detection of Alzheimer disease, (20100000), vol. 67, no. 9, pages 1077 - 1081, XP008181985 [A] 27-31, 53, 55-58 * See the whole document. * DOI: http://dx.doi.org/10.1001/archneurol.2010.215 | by applicant | US2016291036 | - "Association As. 2013 Alzheimer's Disease facts and figures", Alzheimers Dement, (20130000), vol. 9, pages 1 - 72 | - HURD MDMARTORELL PDELAVANDE AMULLEN KJLANGA KM, "Monetary costs of dementia in the United States", N Engl J Med, (20130000), vol. 368, pages 1326 - 1334 | - LYKETSOS CGSZEKELY CAMIELKE MMROSENBERG PBZANDI PP, "Developing new treatments for Alzheimer's disease: The who, what, when, and how of biomarker-guided therapies", Int Psychogeriatr, (20080000), vol. 20, pages 871 - 889 | - HENCHCLIFFE CDODEL RBEAL MF, "Biomarkers of Parkinson's disease and Dementia with Lewy bodies", Prog Neurobiol, (20110000), vol. 95, pages 601 - 613 | - HU WTCHEN-PLOTKIN AARNOLD SEGROSSMAN MCLARK CMSHAW LMMCCLUSKEY LELMAN LKARLAWISH JHURTIG HI, "Biomarker discovery for Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's disease", Acta Neuropathol, (20100000), vol. 120, pages 385 - 399, XP019847038 | - HENEKA MTKUMMER MPLATZ E, "Innate immune activation in neurodegenerative disease", Nat Rev Immunol, (20140000), vol. 14, doi:10.1038/nri3705, pages 463 - 477, XP055473907 DOI: http://dx.doi.org/10.1038/nri3705 | - O'BRYANT SEXIAO GZHANG FEDWARDS MGERMAN DYIN XCOMO TREISCH JHUEBINGER HMGRAFF-RADFORD N, "Validation of a serum screen for Alzheimer's disease across assay platforms, species and tissues", J Alzheimers Dis, (20140000), vol. 42, doi:10.3233/JAD-141041, pages 1325 - 35, XP008181986 DOI: http://dx.doi.org/10.3233/JAD-141041 | - O'BRYANT SEJOHNSON LEDWARDS MSOARES HDEVOUS MDROSS SROHLFING GHALL J, "Texas Research and Care Consortium. The link between c-reactive protein and Alzheimer's disease among Mexican Americans", J Alzheimers Dis, (20130000), vol. 34, pages 701 - 706 | - O'BRYANT SEXIAO GBARBER RREISCH JDOODY RFAIRCHILD TADAMS PWARING SDIAZ- ARRASTIA R, "Texas Alzheimer's Research Consortium. A serum protein-based algorithm for the detection of Alzheimer disease", Arch Neurol, (20100000), vol. 67, pages 1077 - 1081 | - O'BRYANT SEXIAO GBARBER RHUEBINGER RWILHELMSEN KEDWARDS MGRAFF-RADFORD NDOODY RDI, "A blood-based screening tool for Alzheimer's disease that spans serum and plasma: Findings from TARC and ADNI", PLoS ONE, (20110000), vol. 6, page e28092 | - O'BRYANT SXIAO GBARBER RREISCH JHALL JCULLUM CMDOODY RFAIRCHILD TADAMS PWILHELMSEN K, "A blood based algorithm for the detection of Alzheimer's disease", Dement Geriatr Cogn Disord, (20110000), vol. 32, doi:10.1159/000330750, pages 55 - 62, XP055209773 DOI: http://dx.doi.org/10.1159/000330750 | - O'BRYANT SEWARING SCHOBSON VHALL JRMOORE CBBOTTIGLIERI TMASSMAN PDIAZ- ARRASTIA R, "Decreased C-reactive protein levels in alzheimer disease", J Geriatr Psychiatry Neurol, (20100000), vol. 23, doi:10.1177/0891988709351832, pages 49 - 53, XP055360633 DOI: http://dx.doi.org/10.1177/0891988709351832 | - SCHMIDT RSCHMIDT HCURB JDMASAKI KWHITE LRLAUNER LJ, "Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study", Ann Neurol, (20020000), vol. 52, pages 168 - 174 | - IN'T VELD BARUITENBERG, AHOFMAN, ALAUNER, LJVAN DUIJNCM, STIJNENT, BRETELER MMSTRICKER BH, "Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease", N Engl J Med, (20010000), vol. 345, doi:10.1056/NEJMoa010178, pages 1515 - 1521, XP055017404 DOI: http://dx.doi.org/10.1056/NEJMoa010178 | - ANTHONY JCBREITNER JCZANDI PPMEYER MRJURASOVA INORTON MCSTONE SV, "Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists: the Cache County study", Neurology, (20000000), vol. 54, pages 2066 - 2071 | - ETMINAN MGILL SSAMII A, "Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: Systematic review and meta-analysis of observational studies", BMJ, (20030000), vol. 327, page 128 | - AISEN PSSCHAFER KAGRUNDMAN MPFEIFFER ESANO MDAVIS KLFARLOW MRJIN STHOMAS RGTHAL LJ, "Alzheimer's Disease Cooperative Study. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial", JAMA, (20030000), vol. 289, pages 2819 - 2826 | - GASPARINI LONGINI EWENK G, "Non-steroidal anti-inflammatory drugs (NSAIDs) in Alzheimer's disease: Old and new mechanisms of action", J Neurochem., (20040000), vol. 91, doi:10.1111/J.1471-4159.2004.02743.X, pages 521 - 536, XP002671653 DOI: http://dx.doi.org/10.1111/J.1471-4159.2004.02743.X | - HIROHATA MONO KNAIKI HYAMADA M, "Non-steroidal anti-inflammatory drugs have anti- amyloidogenic effects for Alzheimer's B-amyloid fibrils in vitro", Neuropharmacology, (20050000), vol. 49, doi:10.1016/j.neuropharm.2005.07.004, pages 1088 - 1099, XP026192891 DOI: http://dx.doi.org/10.1016/j.neuropharm.2005.07.004 | - KLEGERIS AMCGEER PL, "Non-steroidal anti-inflammatory drugs (NSAIDs) and other anti- inflammatory agents in the treatment of neurodegenerative disease", Curr Alzheimer Res, (20050000), vol. 2, doi:10.2174/1567205054367883, pages 355 - 365, XP009128606 DOI: http://dx.doi.org/10.2174/1567205054367883 | - THAL LJFERRIS SHKIRBY LBLOCK GALINES CRYUEN EASSAID CNESSLY MLNORMAN BABARANAK CC, "Rofecoxib Protocol 078 study group. A randomized, double- blind, study of rofecoxib in patients with mild cognitive impairment", Neuropsychopharmacology, (20050000), vol. 30, pages 1204 - 1215 | - AISEN PSSCHAFER KAGRUNDMAN MKNOPMAN DTABET N, "Neither rofecoxib nor naproxen slows cognitive decline in people with mild-to-moderate Alzheimer's disease", Evidence- Based Healthcare, (20030000), vol. 7, pages 200 - 201 | - ADAPT RESEARCH GROUPLYKETSOS CGBREITNER JCGREEN RCMARTIN BKMEINERT CPIANTADOSI SSABBAGH M, "Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial", Neurology, (20070000), vol. 68, pages 1800 - 1808 | - GRUNDMAN MTHAL JL, "Treatment of Alzheimer's disease: rationale and strategies", Neurologic Clinics, (20000000), vol. 18, pages 807 - 827 | - O'BRYANT SEXIAO GEDWARDS MDEVOUS MGUPTA VBMARTINS RZHANG FBARBER R, "Texas Alzheimer's Research and Care Consortium (TARCC). Biomarkers of Alzheimer's disease among Mexican Americans", J Alzheimers Dis, (20130000), vol. 34, pages 841 - 849 | - DUONG TNIKOLAEVA MACTON PJ, "C-reactive protein-like immunoreactivity in the neurofibrillary tangles of Alzheimer's disease", Brain Res, (19970000), vol. 749, doi:10.1016/S0006-8993(96)01359-5, pages 152 - 156, XP001019691 DOI: http://dx.doi.org/10.1016/S0006-8993(96)01359-5 | - IWAMOTO NNISHIYAMA EOHWADA JARAI H, "Demonstration of CRP immunoreactivity in brains of Alzheimer's disease: immunohistochemical study using formic acid pretreatment of tissue sections", Neurosci Lett, (19940000), vol. 177, doi:10.1016/0304-3940(94)90035-3, pages 23 - 26, XP025829984 DOI: http://dx.doi.org/10.1016/0304-3940(94)90035-3 | - BREITNER JCBAKER LDMONTINE TJMEINERT CLLYKETSOS CGASHE KHBRANDT JCRAFT SEVANS DEGREEN RC, "ADAPT Research Group. Extended results of the Alzheimer's disease anti-inflammatory prevention trial", Alzheimers Dement, (20110000), vol. 7, pages 402 - 411 | - MCGEER EGMCGEER PL, "The importance of inflammatory mechanisms in Alzheimer disease", Exp Gerontol, (19980000), vol. 33, pages 371 - 378 | - GOTTSCHALL PE, "Beta-amyloid induction of gelatinase B secretion in cultured microglia: inhibition by dexamethasone and indomethacin", Neuroreport, (19960000), vol. 7, pages 3077 - 3080, XP002070236 | - NETLAND EENEWTON JLMAJOCHA RETATE BA, "Indomethacin reverses the microglial response to amyloid beta", Neurobiol Aging, (19980000), vol. 19, pages 201 - 204 | - MACKENZIE IRMUNOZ DG, "Nonsteroidal anti-inflammatory drugs use and Alzheimer-type pathology in aging", Neurology, (19980000), vol. 50, pages 986 - 990 | - ROGERS JKIRBY LCHEMPELMAN SRBERRY DLMCGEER PLKASZNIAK AWZALINSKI JCOFIELD MMANSUKHANI LWILLSON P et al., "Clinical trial of indomethacin in Alzheimer's disease", Neurology, (19930000), vol. 43, pages 1609 - 1611, XP002070235 | - TOCCO GFREIRE-MOAR JSCHREIBER SSSAKHI SHAISEN PSPASINETTI GM, "Maturational regulation and regional induction of cyclooxygenase-2 in rat brain: implications for Alzheimer's disease", Exp Neurol, (19970000), vol. 144, pages 339 - 349 | - PASINETTI GMAISEN PS, "Clycooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain", Neuroscience, (19980000), vol. 87, pages 319 - 324 | - HALL JRWIECHMANN ARJOHNSON LAEDWARDS MBARBER RCCUNNINGHAM RSINGH MO'BRYANT SE, "The impact of APOE status on relationship of biomarkers of vascular risk and systemic inflammation to neuropsychiatric symptoms in Alzheimer's disease", J Alzheimers Dis, (20140000), vol. 40, pages 887 - 896 | - O'BRYANT SEJOHNSON LREISCH JEDWARDS MHALL JBARBER RDEVOUS DM SRROYALL DSINGH M, "Risk factors for mild cognitive impairment among Mexican Americans", Alzheimers Dement, (20130000), vol. 9, pages 622 - 631 | - CUNNINGHAM RLSINGH MO'BRYANT SEHALL JRBARBER RC, "Oxidative stress, testosterone, and cognition among caucasian and mexican-american men with and without Alzheimer's disease", J Alzheimers Dis, (20140000), vol. 40, pages 563 - 573 | - JOHNSON LAHALL JRO'BRYANT SE, "A Depressive Endophenotype of Mild Cognitive Impairment and Alzheimer's Disease", PLoS ONE, (20130000), vol. 8, page e68848 | - JOHNSON LASOHRABI HRHALL JRTADDEI KEDWARDS MMARTINS RN, "A depressive endophenotype of poorer cognition among cognitively healthy community- dwelling adults: Results from the Western Australia Memory Study", Int J Geriatr Psychiatry, (20150800), vol. 30, no. 8, pages 881 - 6 |